ライフサイエンスコーパス: Rous

1 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

2 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

3 Rous sarcoma virus (RSV) budding requires an interaction

4 Rous sarcoma virus (RSV) promoter-driven expression of t

5 Rous sarcoma virus (RSV) requires large amounts of unspl

6 Rous sarcoma virus (RSV), a simple retrovirus, needs to

7 Rous sarcoma virus (RSV)-tk bearing the HSV1-tk gene wer

8 Rous sarcoma virus pre-mRNA contains an element known as

9 Rous sarcoma virus RNA contains a negative regulator of

10 Rous spent his entire research career at The Rockefeller

11 human immunodeficiency virus type 1 (HIV-1), Rous sarcoma virus (RSV), and Mason-Pfizer monkey virus

12 novirus containing the HERG gene driven by a Rous sarcoma virus (RSV) promoter.

13 as an inducible HIV-1 genome controlled by a Rous sarcoma virus promoter with lac operator sequences.

14 We have constructed and characterized a Rous sarcoma virus-based retroviral vector with the host

15 of the NC domain in assembly of VLPs from a Rous sarcoma virus (RSV) Gag protein and have characteri

16 In this report, a Rous sarcoma virus (RSV) mutant having two acidic-to-bas

17 The cellular receptor for subgroup A Rous sarcoma virus (RSV) contains a single LDL-A module

18 Tva is the receptor for subgroup A Rous sarcoma virus, and it contains a single LDL-A modul

19 It was shown previously that a Rous sarcoma virus Gag protein missing only the protease

20 endogenously expressing SDF-1/CXCL12 under a Rous sarcoma virus promoter were produced.

21 ol vector containing a constitutively active Rous sarcoma virus (RSV) viral promoter driving the luci

22 riptional control of a constitutively active Rous sarcoma virus promoter was regulated identically to

23 eplication-defective adenoviral vectors [Adv.Rous sarcoma virus (RSV)-nf] representing three families

24 a mouse monoclonal antibody directed against Rous sarcoma virus (RSV) subgroup A Env that will be use

25 ssed this question using the alpharetrovirus Rous sarcoma virus (RSV) as a model system.

26 we have examined whether the alpharetrovirus Rous sarcoma virus (RSV) is susceptible to inhibition by

27 , a Gammaretrovirus, and the Alpharetrovirus Rous sarcoma virus (RSV), were susceptible to inhibition

28 -membrane interaction of the alpharetrovirus Rous sarcoma virus (RSV).

29 this model, CA proteins from both HIV-1 and Rous sarcoma virus (RSV) form similar hexagonal lattices

30 In HIV-1 and Rous sarcoma virus, this region forms a rod-like structu

31 an immunodeficiency virus type 1 (HIV-1) and Rous sarcoma virus (RSV) capsid proteins form a beta-hai

32 ts within the avian leukosis virus (ALV) and Rous sarcoma virus (RSV) LTR enhancers in a pattern iden

33 V), feline immunodeficiency virus (FIV), and Rous sarcoma virus (RSV) to critically address the role

34 ogous positions in visna virus integrase and Rous sarcoma virus integrase changed the target site pre

35 tures found in osteoclasts, macrophages, and Rous sarcoma virus (RSV)-transformed fibroblasts.

36 unodeficiency virus type 1, visna virus, and Rous sarcoma virus exhibited different target site prefe

37 o- deficiency virus type 1, visna virus, and Rous sarcoma virus exhibited distinct preferences for wa

38 1) and 2, simian immunodeficiency virus, and Rous sarcoma virus.

39 t, the L domains of oncoretroviruses such as Rous sarcoma virus (RSV) have a more N-terminal location

40 ture of the CA domains in immature assembled Rous sarcoma virus Gag particles.

41 ent of Gag in in vivo and in vitro assembled Rous sarcoma virus (RSV) particles and to compare these

42 ng a well-established retroviral model-avian Rous sarcoma virus (RSV)-we analyzed changes in an RSV v

43 Production of avian Rous-associated virus type 1 was also impaired by PARP-1

44 e experiments reported here, using the avian Rous sarcoma virus as a model system, further define the

45 ct of the retroviral M domain from the avian Rous sarcoma virus is defined and its solution structure

46 In particular, although both Rous sarcoma virus (RSV) and AMV could replicate in cult

47 tained human factor IX (hFIX) cDNA driven by Rous sarcoma virus long terminal repeat in the E1 region

48 r carrying the cDNA for C/EBPalpha driven by Rous sarcoma virus promoter elements (AdCEBPalpha) or a

49 ansforming viral oncogene product encoded by Rous sarcoma virus (RSV).

50 chicken embryo fibroblasts (CEF) infected by Rous sarcoma virus against a confluent background of uni

51 Cell transformation by Rous sarcoma virus results in a dramatic change of adhes

52 In chick embryo fibroblasts transformed by Rous sarcoma virus (RSV) the tyrosine phosphorylation of

53 er ALV was found in stocks of RSV and called Rous-associated virus (RAV).

54 essential steps in understanding the chicken Rous sarcoma virus (RSV) genome association with a nonpe

55 ld be initiated by electroporation of cloned Rous sarcoma virus (RSV) proviral DNA into the developin

56 cytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity.

57 We have identified an assembly-defective Rous sarcoma virus (RSV) Gag mutant that retains signifi

58 plasmid acceptor, purified bacterium-derived Rous sarcoma virus integrase (IN), and a host cell DNA-b

59 f a weak src 3'ss is necessary for efficient Rous sarcoma virus replication.

60 s containing TATA and/or initiator elements, Rous sarcoma virus and thymidine kinase promoters in BeW

61 Although the integrity of the entire Rous sarcoma virus leader sequence is important for retr

62 rescence correlation spectroscopy-to examine Rous sarcoma virus Gag-Gag and -membrane interactions in

63 For Rous sarcoma virus (RSV), Gag proteins are synthesized i

64 For Rous sarcoma virus (RSV), the size determinant maps to t

65 iruses containing the cellular receptors for Rous sarcoma virus (Tva) or ecotropic murine leukemia vi

66 Since codon composition values for Rous sarcoma virus distinguished a "foreign" gene from t

67 ive regulator of splicing (NRS) element from Rous sarcoma virus.

68 odel retroviral envelope protein (EnvA) from Rous sarcoma virus (RSV).

69 structure of the three-domain integrase from Rous sarcoma virus in complex with viral and target DNAs

70 he negative regulator of splicing (NRS) from Rous sarcoma virus suppresses viral RNA splicing and is

71 totally unrelated late domain sequences from Rous sarcoma virus (contained in its p2b sequence) or eq

72 natural or mutated 5' leader sequences from Rous sarcoma virus were expressed in avian cells in the

73 e-bound nonreceptor tyrosine kinase Src from Rous sarcoma virus, these interactions are mediated by a

74 variety of specimens assembled in vitro from Rous sarcoma virus (RSV) CA.

75 only 2.6-fold less efficiently than genomic Rous sarcoma virus RNA.

76 downstream from the 3'ss of the heterologous Rous sarcoma virus src gene.

77 triphosphate [PI(3,4,5)P(3)] levels impaired Rous sarcoma virus (RSV) Gag PM localization.

78 In Rous sarcoma virus, previous studies have identified imp

79 In Rous sarcoma virus, splicing control is achieved in part

80 the robustly induced enzymatic activities in Rous sarcoma virus (RSV)-transformed chicken cells.

81 erve as mRNA for the envelope protein and in Rous sarcoma virus as src mRNA.

82 ng (NRS) is a long cis-acting RNA element in Rous sarcoma virus that contributes to unspliced RNA acc

83 is tyrosine-phosphorylated when expressed in Rous sarcoma virus-infected chicken embryo fibroblasts (

84 peat (DR) sequences flanking the src gene in Rous sarcoma virus are essential posttranscriptional con

85 osed based on the existence of MA mutants in Rous sarcoma virus (RSV), murine leukemia virus, human i

86 stablishment of the transformed phenotype in Rous sarcoma virus (RSV)-infected cells.

87 initially identified as a phosphoprotein in Rous sarcoma virus-transformed cells.

88 gate Gag protein structure and processing in Rous sarcoma virus, the prototype of the avian sarcoma a

89 About one-third of the MA protein in Rous sarcoma virus (RSV) is phosphorylated.

90 by his discovery of reverse transcriptase in Rous sarcoma virus virions.

91 In some orthoretroviruses, including Rous Sarcoma Virus (RSV), CA carries a short and hydroph

92 virus-based vector LNCX, contain an internal Rous sarcoma virus (RSV) or cytomegalovirus (CMV) promot

93 and -uncoupled pathways; the latter involved Rous sacracoma virus homolog genes-encoded tyrosine kina

94 tudy in vitro-assembled, immature virus-like Rous sarcoma virus (RSV) Gag particles and have determin

95 in vitro flotation assay to directly measure Rous sarcoma virus (RSV) MA-membrane interaction in the

96 HIV-1, Moloney murine leukemia virus (MLV), Rous sarcoma virus (RSV), and human T-cell lymphotropic

97 roviruses that undergo type C morphogenesis, Rous sarcoma virus and human immunodeficiency virus, whi

98 e 3' splice site in the BPV-1 late pre-mRNA, Rous sarcoma virus src pre-mRNA, human immunodeficiency

99 We have previously described a mutant Rous sarcoma virus (RSV) Env protein, Env-mu26, with an

100 We previously reported that a mutant Rous sarcoma virus (RSV) with an alternate polypurine tr

101 enzyme, resulting in a highly active mutant Rous sarcoma virus (RSV) protease that displays many cha

102 We have examined mutant Rous sarcoma virus envelope proteins with truncations or

103 erminal 100 residues of the non-myristylated Rous sarcoma virus (RSV) Gag protein.

104 the utility of the system, we developed new Rous sarcoma virus (RSV)-based replication-incompetent v

105 HT29, and CaCo2) compared with a nonspecific Rous sarcoma virus-yCD virus.

106 nhanced when the serine at amino acid 124 of Rous sarcoma virus (RSV) integrase is replaced by alanin

107 sembly incompetent by testing the ability of Rous sarcoma virus (RSV) CA-SP to assemble in vitro into

108 immunodeficiency virus type 1 (HIV-1) and of Rous sarcoma virus (RSV) are morphologically distinct wh

109 d-state NMR (ssNMR) resonance assignments of Rous sarcoma virus (RSV) CA, assembled into hexamer tube

110 nalyses of two in-vitro-assembled capsids of Rous sarcoma virus.

111 In the case of Rous sarcoma virus (RSV), the size determinant maps to t

112 The discovery of Rous sarcoma virus (RSV) led to the identification of ce

113 The discovery of Rous sarcoma virus, which was reported by Peyton Rous in

114 The major late domain of Rous sarcoma virus (RSV) has been mapped to a PPPY motif

115 The L domain of Rous sarcoma virus (RSV) has been shown to interact with

116 A PPPPY motif within the L domain of Rous sarcoma virus (RSV) was previously characterized as

117 resembles the PPPPY motif in the L domain of Rous sarcoma virus (RSV), an avian retrovirus.

118 ences that exist in the C-terminal domain of Rous sarcoma virus capsid relative to the other capsid p

119 here that while deletion of the NC domain of Rous sarcoma virus Gag abolishes formation and budding o

120 The late assembly domain (L-domain) of Rous sarcoma virus (RSV) or human immunodeficiency virus

121 membrane binding, we fused the MA domains of Rous sarcoma virus (RSV) and HIV-1 to the chemically ind

122 icles (VLPs), we observed that expression of Rous sarcoma virus Gag failed to produce VLPs.

123 that allowed for the first-time formation of Rous sarcoma virus CA into structures resembling authent

124 ous studies revealed that truncated forms of Rous sarcoma virus integrase containing two of the three

125 med spontaneously in vitro from fragments of Rous sarcoma virus (RSV) Gag protein purified after expr

126 homologue of v-src, the transforming gene of Rous Sarcoma virus.

127 ned 70S RNA closely related to the genome of Rous-associated virus type 0, but identifiable as the ev

128 resolution of a fragment of the integrase of Rous sarcoma virus (residues 49-286) containing both the

129 that of the naturally nonmyristoylated MA of Rous sarcoma virus.

130 During assembly and morphogenesis of Rous sarcoma virus (RSV), proteolytic processing of the

131 structure of the N-terminal domain (NTD) of Rous sarcoma virus (RSV) capsid protein (CA), with an up

132 dentified in the gag-specific protein p2b of Rous sarcoma virus.

133 Expression of the Gag-Pol polyprotein of Rous sarcoma virus (RSV) requires a -1 ribosomal framesh

134 t the enzymatic and structural properties of Rous sarcoma virus (RSV) PR are exquisitely sensitive to

135 The Gag protein of Rous sarcoma virus (RSV) can direct particle assembly an

136 describes new mutations in the CA protein of Rous sarcoma virus (RSV) that were designed to test whet

137 ne transport, the multidomain Gag protein of Rous sarcoma virus (RSV) undergoes importin-mediated nuc

138 a mutant of the viral matrix (MA) protein of Rous sarcoma virus that disrupts viral RNA dimerization.

139 domain that is present in the Gag protein of Rous sarcoma virus.

140 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

141 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

142 ric interactions between the Gag proteins of Rous sarcoma virus (RSV).

143 The 5' untranslated region of Rous sarcoma virus (RSV) RNA is a highly ordered structu

144 inding site in the 5' untranslated region of Rous sarcoma virus (RSV) RNA play an integral role in mu

145 ing element in the 3' untranslated region of Rous sarcoma virus (RSV) RNA was found to promote Rev-in

146 the cell dramatically reduced the release of Rous sarcoma virus, an avian retrovirus.

147 to as antisense, can inhibit replication of Rous sarcoma virus through hybridization to viral RNA.

148 er of cis-acting sequences within the RNA of Rous sarcoma virus play a role in preserving a large poo

149 In vivo screening of Rous sarcoma virus mutants was performed with randomly m

150 eption was the 11-amino-acid p2b sequence of Rous sarcoma virus (RSV) Gag, which could fully restore

151 L vitiligo by using the complete sequence of Rous-associated virus-2 as a probe for EV.

152 onducted to investigate the initial steps of Rous sarcoma virus (RSV) assembly by examining the assoc

153 the Gag protein; however, recent studies of Rous sarcoma virus (RSV) and human immunodeficiency viru

154 n the SU and TM envelope protein subunits of Rous sarcoma virus and murine leukemia virus.

155 d CRM1-dependent nuclear cycling was that of Rous sarcoma virus (RSV).

156 ze budding of virus-like particles (VLPs) of Rous sarcoma virus (RSV) and HIV type 1 (HIV-1).

157 eplication-competent shuttle vector based on Rous sarcoma virus (RSV), with alternate retroviral PPTs

158 ses, including the prototypic oncoretrovirus Rous sarcoma virus, were synthesized on cytosolic riboso

159 However, in the presence of budding HIV-1 or Rous sarcoma virus (RSV) particles, some glycoproteins,

160 from human immunodeficiency virus type 1 or Rous sarcoma virus, respectively.

161 ontrol of the human cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoters.

162 HIT, and CHO cells using cytomegalovirus or Rous sarcoma virus promoters.

163 , human immunodeficiency virus type 1 p6, or Rous sarcoma virus p2b.

164 mmunodeficiency virus type 1 (HIV-1) PTAP or Rous sarcoma virus (RSV) PPPY L domain in the p9 protein

165 Peyton Rous and others demonstrated the process of co-carcinoge

166 Peyton Rous founded this scientific field in 1911 by discoverin

167 One hundred years ago Peyton Rous recovered a virus, now known as the Rous sarcoma vi

168 sarcoma virus, which was reported by Peyton Rous in the Journal of Experimental Medicine 100 years a

169 vector encoding a peptide inhibitor of PKA [Rous sarcoma virus (RSV)-protein kinase A inhibitor (PKI

170 binding chicken Y-box protein that promotes Rous sarcoma virus long terminal repeat (RSV LTR)-driven

171 ssociation of HIV-1 Gag, as well as purified Rous sarcoma virus (RSV) MA and Gag, depends strongly on

172 We have purified Rous sarcoma virus (RSV) Gag protein and in parallel sev

173 Using purified Rous sarcoma virus Gag and Gag truncations, we studied t

174 is virus integrase and bacterial recombinant Rous sarcoma virus (Prague A strain) integrase (approxim

175 Site-directed mutagenesis of recombinant Rous sarcoma virus (RSV) integrase (IN) allowed us to ga

176 of four promoters (dihydrofolate reductase, Rous sarcoma virus, long terminal repeat, or cytomegalov

177 nducible, constitutively expressed reporter, Rous sarcoma virus-luciferase (RSV-LUC); nor does it blo

178 articles of the prototypic avian retrovirus, Rous sarcoma virus (RSV), by using scanning transmission

179 We asked whether a single Rous sarcoma virus (RSV) RNA can be translated and subse

180 produce milligram quantities of the soluble Rous sarcoma virus (RSV) synaptic complex that is kineti

181 We produced kinetically stabilized Rous sarcoma virus (RSV) intasomes with human immunodefi

182 A direct comparison demonstrates that Rous sarcoma virus is capable of infecting aphidicolin-a

183 We find that Rous sarcoma virus virions, like the human immunodeficie

184 The Rous sarcoma virus (RSV) Gag polyprotein undergoes trans

185 The Rous sarcoma virus (RSV) Gag precursor polyprotein is th

186 The Rous sarcoma virus (RSV) is an exception, in that its ge

187 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

188 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

189 The Rous sarcoma virus (RSV) negative regulator of splicing

190 The Rous sarcoma virus (RSV) polyadenylation site (PAS) is v

191 The Rous sarcoma virus (RSV) transmembrane (TM) glycoprotein

192 The Rous sarcoma virus gag gene contains a cis-acting negati

193 The Rous sarcoma virus Gag protein undergoes transient nucle

194 The Rous sarcoma virus protease displays a high degree of sp

195 1 is shown to transcriptionally activate the Rous sarcoma virus-long terminal repeat promoter, which

196 ton Rous recovered a virus, now known as the Rous sarcoma virus (RSV), from a chicken sarcoma, which

197 Other substrates such as the Rous sarcoma virus protein NC are phosphorylated by gamm

198 olecular disulfide bond during assembly, the Rous sarcoma virus capsid protein does not.

199 he cDNA for human iNOS was cloned behind the Rous sarcoma virus (RSV) promoter to create adenovirus (

200 on of baby hamster kidney fibroblasts by the Rous sarcoma virus causes a significant increase in the

201 antibiotic-resistance gene was driven by the Rous sarcoma virus long terminal repeat or the herpes si

202 ngeable late assembly domains carried by the Rous sarcoma virus p2b protein and human immunodeficienc

203 which sig-mEndo expression was driven by the Rous sarcoma virus promoter had moderately high serum le

204 porter beta-galactosidase gene driven by the Rous Sarcoma Virus promoter.

205 ch controls fibroblast transformation by the Rous sarcoma virus.

206 eat honor that my work was recognized by the Rous-Whipple Award this past year, giving me the opportu

207 cloned into a pMAMneo vector containing the Rous sarcoma virus promoter and the neomycin resistance

208 135-nucleotide (nt) direct repeats flank the Rous sarcoma virus (RSV) oncogene src and are composed o

209 0 amino acid residue capsid protein from the Rous sarcoma virus has been determined by NMR methods.

210 2(1) collagen promoters and 10-fold from the Rous sarcoma virus long terminal repeat.

211 We previously identified the Rous sarcoma virus (RSV) stability element (RSE), an RNA

212 In the Rous sarcoma virus (RSV) Gag protein, the 25 amino-acid

213 In the Rous sarcoma virus (RSV) Gag protein, the M domain is co

214 the site phosphorylated by gamma-PAK in the Rous sarcoma virus nucleocapsid protein NC in vivo and i

215 Instead, the Rous sarcoma virus capsid protein contains a single cyst

216 During virion maturation, the Rous sarcoma virus (RSV) capsid protein is cleaved from

217 The first few residues of the Rous sarcoma virus (RSV) CA protein comprise a structura

218 of charged residues in the FL region of the Rous sarcoma virus (RSV) CA to particle assembly.

219 The p2 region of the Rous sarcoma virus (RSV) Gag polyprotein contains an ass

220 Nucleocytoplasmic shuttling of the Rous sarcoma virus (RSV) Gag polyprotein is an integral

221 Proteolytic processing of the Rous sarcoma virus (RSV) Gag precursor was altered in vi

222 The first 86 residues of the Rous sarcoma virus (RSV) Gag protein form a membrane-bin

223 ously reported that nuclear transport of the Rous sarcoma virus (RSV) Gag protein is intrinsic to the

224 ped three very small, modular regions of the Rous sarcoma virus (RSV) Gag protein that are necessary

225 een these two hypotheses, we made use of the Rous sarcoma virus (RSV) Gag protein, the PR of RSV IS i

226 elatively short, 82 nucleotide region of the Rous sarcoma virus (RSV) genome, called muPsi, was shown

227 taining the ts gene under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

228 eracts with the Schmidt-Ruppin strain of the Rous sarcoma virus (RSV) long terminal repeat (LTR) betw

229 CC-3' present on the noncoding strand of the Rous sarcoma virus (RSV) long terminal repeat (LTR) in a

230 eceptor (ecoR) cDNA under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) prom

231 rted repeat (IR) within the U5 region of the Rous sarcoma virus (RSV) mRNA forms a structure composed

232 y reactions with purified CA proteins of the Rous sarcoma virus (RSV) were used to define factors tha

233 tween the PBS and the CA dinucleotide of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z to matc

234 the endogenous polypurine tract (PPT) of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z was rep

235 ions in the 5' end of the U3 sequence of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z.

236 +)-ATPase (SERCA2a) under the control of the Rous sarcoma virus (RSV).

237 polyprotein are intrinsic components of the Rous sarcoma virus assembly pathway.

238 of charged amino acids on the surface of the Rous sarcoma virus capsid protein in the assembly of app

239 ed sequence similarity, the structure of the Rous sarcoma virus capsid protein is similar to the stru

240 In the context of the Rous sarcoma virus Gag polyprotein, only the nucleocapsi

241 purified, slightly truncated version of the Rous sarcoma virus Gag protein, Delta MBD Delta PR, and

242 gion, Mpsi, from the 5' leader region of the Rous sarcoma virus genome that is sufficient to direct t

243 ckaging signal, MPsi, from the 5' end of the Rous sarcoma virus genome.

244 ng MyoD under transcriptional control of the Rous sarcoma virus long terminal repeat.

245 To further study the role of the Rous sarcoma virus MA sequence in the viral replication

246 coli lacZ reporter gene under control of the Rous sarcoma virus promoter and mammalian RNA processing

247 ervative substitutions in this region of the Rous sarcoma virus protein were lethal due to a severe d

248 quenced a small segment of the 3' end of the Rous sarcoma virus, just inside the poly(A) tail, at the

249 o -90 confers FGF2/FSK responsiveness on the Rous sarcoma virus minimal promoter.

250 alovirus (CMV) immediate-early promoter, the Rous sarcoma virus (RSV) long terminal repeat, and the a

251 As also found for other retroviruses, the Rous sarcoma virus structural protein Gag is necessary a

252 We discovered that the Rous sarcoma virus (RSV) Gag protein transiently localiz

253 discovery from Ray Erikson's group that the Rous sarcoma virus (RSV) v-Src-transforming protein had

254 at Y951 facilitates binding of VEGFR2 to the Rous sarcoma (Src) homology 2-domain of T cell-specific

255 Using the Rous sarcoma virus-derived vector RCAS, we previously sh

256 ls from the beta-galactosidase gene when the Rous sarcoma virus promoter is used to drive transgene e

257 proteins that specifically interact with the Rous sarcoma virus (RSV) L domain in vitro and in vivo.

258 dogenous AAV promoters, p5 and p40, with the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

259 ilar to the levels observed in vivo with the Rous sarcoma virus long terminal repeat constitutive pro

260 us, all of the functions associated with the Rous sarcoma virus MA sequence must be contained within

261 Examination of the genomes of three Rous sarcoma virus isolates indicated that codon composi

262 By cryoelectron tomography, Rous sarcoma virus VLPs show an organized hexameric latt

263 pHyde gene under the control of a truncated Rous sarcoma virus (RSV) promoter (AdRSVpHyde) was gener

264 ence appears to be modular, as the unrelated Rous sarcoma virus (RSV) Env can be made Vpu sensitive b

265 Accumulation of unspliced Rous sarcoma virus RNA is facilitated in part by a negat

266 We used Rous sarcoma virus (RSV) Gag together with membrane sens

267 ecades of study on an avian RNA tumor virus, Rous sarcoma virus (RSV).

268 e used cryo-electron tomography to visualize Rous sarcoma virus, the prototypic alpharetrovirus.

269 RNA(Lys3) as the replication primer, whereas Rous sarcoma virus (RSV) uses tRNA(Trp).

270 One mechanism by which Rous sarcoma virus achieves incomplete splicing involves

271 virus (EIAV) is functionally homologous with Rous sarcoma virus (RSV) p2b and human immunodeficiency

272 icken embryo fibroblasts (CEF) infected with Rous sarcoma virus (RSV).

273 contrast, CEF cultures heavily infected with Rous sarcoma virus in the same medium underwent pervasiv